Arcturus Therapeutics Ltd Share Price Nasdaq
Equities
IL0011280240
Biotechnology & Medical Research
Sales 2024 * | 147M 11.72B | Sales 2025 * | 241M 19.22B | Capitalization | 717M 57.13B |
---|---|---|---|---|---|
Net income 2024 * | -68M -5.42B | Net income 2025 * | 3M 239M | EV / Sales 2024 * | 2.4 x |
Net cash position 2024 * | 364M 29.01B | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.97 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-154
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Ltd
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 28/02/13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 31/08/19 |
Chief Operating Officer | 45 | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 31/08/19 |
James F. Barlow
BRD | Director/Board Member | 65 | 26/05/18 |
Peter Farrell
CHM | Chairman | 81 | 26/05/18 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+45.77% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |